Superficial bladder cancer: part 1. Update on etiology, classification and natural history

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Heney NM. Natural history of superficial bladder cancer: prognostic features and long-term disease course. Urol. Clin. North Am.19, 429–433 (2002).
   Google Scholar
• AJCC Cancer Staging Manual. Lippincott Raven Pages, PA, USA (1997).
   Google Scholar
• Zeegers MP, Kellen E, Buntinix F et al. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J. Urol.21(6), 392–401 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen SM, Garland EM, St John M et al. Acrolin initiates rat urinary bladder carcinogenesis. Cancer Res.52(13), 3577–3581 (1992).
   PubMed Web of Science ®Google Scholar
• Vineis P, Ronco G. Interindividual variation in carcinogen metabolism and bladder cancer risk. Environ. Health Perspect.98, 95–99 (1992).
   Google Scholar
• Lower GM Jr. Concepts in causality: chemically induced human urinary bladder cancer. Cancer49, 1056–1066 (1982).
   PubMed Web of Science ®Google Scholar
• Yu MC, Skipper PL, Tannenbaum SR et al. Arylamine exposures and bladder cancer risk. Mutat. Res.506–507, 21–28 (2002).
   Google Scholar
• Vineis P, Esteve J, Hartage P et al. Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res.48(13), 3849–3852 (1988).
   PubMed Web of Science ®Google Scholar
• Fleshner N, Garland J, Moadel A et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer86(11), 2337–2345 (1999).
   PubMed Web of Science ®Google Scholar
• Clayson DB. Specific aromatic amines as occupational bladder carcinogens. Natl Cancer Inst. Monogr.58, 15–19 (1981).
   Google Scholar
• Droller MJ. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. J. Urol.160(2), 618 (1998).
   Google Scholar
• Golka K, Wiese A, Assennato G et al. Occupational exposure and urological cancer. World J. Urol.21(6), 382–391 (1998).
   Google Scholar
• Huncharek M, Kupelnick B. Personal use of hair dyes and the risk of bladder cancer: results of a meta-analysis. Public Health Rep.120(1), 31–38 (1985).
   Google Scholar
• Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N. Engl. J. Med.313(5), 292–295 (2005).
   Google Scholar
• Kantor AF, Hartage P, Hoover RN. Urinary tract infection and risk of bladder cancer. Am. J. Epidemiol.119(4), 510–515 (1999).
   Google Scholar
• Mostafa MH, Sheweita SA, O’Conner PJ. Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev.12(1), 97–111 (1984).
   Google Scholar
• Fioriti D, Pietropaolo V, Dal Forno S et al. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. Int. J. Immunopathol. Pharmacol.16(3), 283–288 (1997).
   Google Scholar
• Chow WH, Linbald P, Gridley G et al. Risk of urinary tract cancers following kidney or ureter stones. J. Natl Cancer Inst.89(19), 1453–1457 (2003).
   Google Scholar
• Kaldor JM, Day NE, Kittelmann B et al. Bladder tumors following chemotherapy and radiotherapy for ovarian cancer: a case–control study. Int. J. Cancer63, 1–6 (1995).
   PubMed Web of Science ®Google Scholar
• Cannon J, Linke CA, Cos LR. Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention. Urology38(5), 413–416 (1991).
   PubMed Web of Science ®Google Scholar
• Vena JE, Freudenheim J, Graham S et al. Coffee, cigarette smoking, and bladder cancer in western New York. Ann. Epidemiol.3(6), 586–591 (1993).
   PubMedGoogle Scholar
• Howe GR, Burch JD, Miller AB et al. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J. Natl Cancer Inst.64(4), 701–713 (1980).
   PubMedGoogle Scholar
• Slattery ML, Schumacher MC, West DW et al. Smoking and bladder cancer. The modifying effect of cigarettes on other factors. Cancer61(2), 402–408 (1988).
   PubMed Web of Science ®Google Scholar
• Taylor JM, Weinberger MA, Friedman L. Chronic toxicity and carcinogenicity to the urinary bladder of sodium saccharin in the in utero-exposed rat. Toxicol. Appl. Pharmacol.54, 57–75 (1980).
   PubMed Web of Science ®Google Scholar
• Wynder EL, Stellman SD. Artificial sweetener use and bladder cancer: a case-control study. Science207, 1214–1216 (1980).
   PubMed Web of Science ®Google Scholar
• Morrison AS, Buring JE. Artificial sweeteners and cancer of the lower urinary tract. N. Engl. J. Med.302, 537–541 (1980).
   PubMed Web of Science ®Google Scholar
• Sturgeon SR, Hartge P, Silverman DT et al. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology5, 218–225 (1994).
   PubMed Web of Science ®Google Scholar
• Fradet Y. Markers of prognosis in superficial bladder cancer. Semin. Urol.10, 28–38 (1992)
   Google Scholar
• Kotake T, Saiki S, Kinouchi T et al. Detection of the cmyc gene product in urinary bladder cancer. Jpn J. Cancer Res.81, 1198–1201 (1990).
   Google Scholar
• Moriyama M, Akiyama T, Yamamoto T et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol.145, 423–427 (1991).
   PubMed Web of Science ®Google Scholar
• Miyao N, Tsai YC, Lerner SP et al. Role of chromosome 9 in human bladder cancer. Cancer Res.53(17), 4066–4070 (1993).
   PubMed Web of Science ®Google Scholar
• Kruger S, Mahnken A, Kausch I, Feller AC. p16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur. Urol.47(4), 463–467 (2005).
   PubMed Web of Science ®Google Scholar
• Simoneau AR, Spruck CH 3rd, Gonzalez-Zulueta M et al. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS 1 and PTC mutations. Cancer Res.56, 5039–5043 (1996).
   Google Scholar
• Hernandez S, Lopez-Knowles E, Lloreta J et al. Real FX. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol.24(22), 3664–3671 (2006).
   PubMed Web of Science ®Google Scholar
• Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science252, 706 (1991).
   PubMed Web of Science ®Google Scholar
• Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer9, 108–118 (1994).
   Google Scholar
• Ishikawa J, Xu HJ, Hu SX et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res.51, 5736–5743 (1991).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res.58(6), 1090–1094 (1998).
   PubMed Web of Science ®Google Scholar
• Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol. Clin. North Am.19, 455–465 (1992).
   Google Scholar
• Varkarakis MJ, Gaeta J, Moore RH et al. Superficial bladder tumor: aspects of clinical progression. Urology4, 414–420 (1974).
   PubMedGoogle Scholar
• Lee LW, Davis E Jr. Gross urinary hemorrhage: a symptom, not a disease. JAMA153, 782–784 (1953).
   PubMed Web of Science ®Google Scholar
• Sultana SR, Goodman CM, Byrne DJ et al. Microscopic haematuria urological investigation using a standard protocol Br. J. Urol.78, 691–698 (1996).
   PubMedGoogle Scholar
• Messing EM, Young TB, Hunt VB et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J. Urol.137, 919–922 (1987).
   PubMed Web of Science ®Google Scholar
• Grossfeld GD, Wolf JS Jr, Litwan MS et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am. Fam. Physician63(6), 1145–1154 (2001).
   PubMed Web of Science ®Google Scholar
• Badalament RA, Hermansen DK, Kimmel M et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer60(7), 1423–1427 (1987).
   PubMed Web of Science ®Google Scholar
• Farrow GM, Utz DC, Rife CC et al Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res.37, 2794–2798(1977).
   PubMed Web of Science ®Google Scholar
• Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology26(4 Suppl.) 39–46 (1985).
   PubMed Web of Science ®Google Scholar
• Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J. Urol.124, 23–26 (1980).
   PubMed Web of Science ®Google Scholar
• Haleblian GE, Skinner EC, Dickinson MG et al. Hydronephrosis as a prognostic indicator in bladder cancer patients. J. Urol.160 (6 Pt 1), 2011–2014 (1998).
   Google Scholar
• van der Meijden A, Sylvester R, Collette L et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors a combined analysis of 5 EORTC cancer trials. J. Urol.164, 1533–1537 (2000).
   PubMed Web of Science ®Google Scholar
• Witjes JA, Kiemeney LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br. J. Urol.73, 172–176 (1994).
   PubMedGoogle Scholar
• Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol.162, 74–76 (1999).
   PubMed Web of Science ®Google Scholar
• Dutta SC, Smith JA Jr, Shappell SB et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol.166, 490–493 (2001).
   PubMed Web of Science ®Google Scholar
• Balbay MD, Cimentepe E, Unsal A et al. The actual incidence of bladder perforation following transurethral bladder surgery. J. Urol.174(6), 2260–2262 (2005).
   PubMed Web of Science ®Google Scholar
• Canales BK, Anderson JK, Premoli J et al. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage Ta bladder cancer. J. Urol.175(1), 74–77 (2006)
   PubMedGoogle Scholar
• Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J. Urol.164, 1183–1187 (2000).
   PubMed Web of Science ®Google Scholar
• Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J. Urol.156, 1286–1287 (1996).
   PubMed Web of Science ®Google Scholar
• Hofstäder F, Delgado R, Jakse G et al. Urothelial dysplasia and carcinoma in situ of the bladder. Cancer57, 356–361 (1986).
   Google Scholar
• Kiemeney LA, Witjes JA, Hiejbroek RP et al. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur. J. Cancer30A(11), 1621–1625 (1994).
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group Phase II protocol 30861. Eur. Urol.40, 144–150 (2001).
   PubMed Web of Science ®Google Scholar
• Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette–Guerin without maintenance. J. Urol.167(6), 2408–2412 (2002).
   PubMed Web of Science ®Google Scholar
• de Reijke TM, Kurth KH, Sylvester RJ et al. Bacillus Calmette–Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer – Genito-Urinary Group Phase III Trial (30906). J. Urol.173(2), 405–409 (2005).
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Wijkstrom H, Malmstrom PU et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur. Urol.43(6), 637–645 (2003).
   PubMed Web of Science ®Google Scholar
• Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer74(1), 115–122 (1994).
   PubMed Web of Science ®Google Scholar
• Murphy WM, Emerson LD, Chandler RW et al. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J. Urol.136, 815–819 (2002).
   Google Scholar
• Schmidbauer J, Witjes F, Schmeller N et al. For the Hexvix PCB301/01 Study Group: Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol.171, 135–138 (2004).
   PubMed Web of Science ®Google Scholar
• D’Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur. Urol.42, 417–425 (2002).
   PubMed Web of Science ®Google Scholar
• The Bladder Consensus Conference Committee, Epstein JI, Amin MB, ReuterVE et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol.12, 1435–1448 (1998).
   Google Scholar
• Sauter G, Algaba F, Amin M et al. Non-invasive urothelial neoplasias. WHO classification of non invasive papillary urothelial neoplasias. WHO Classification of non invasive papillary urothelial tumors. In: WHO Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein JL et al. (Eds). IARCC Press, Lyon, France, 110 (2004).
   Google Scholar
• Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J. Urol.168(3), 968–972 (2002).
   PubMed Web of Science ®Google Scholar
• Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int. J. Surg. Pathol.13(2), 143–153 (2005).
   PubMed Web of Science ®Google Scholar
• Magi-Galluzzi C, Epstein JI. Urothelial papilloma of the bladder: a review of 34 de novo cases. Am. J. Surg. Pathol.28(12), 1615–1620 (2004).
   Google Scholar
• American Joint Committee on Cancer. Urinary bladder. In: AJCC Cancer Staging Manual. 6th Edition. Springer, NY, USA 335–340 (2002).
   Google Scholar
• Algaba F. Origin of high-grade superficial bladder cancer. Eur. Urol.13, 153–155 (1987).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, el-Mekresh MM, el-Baz MA et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol.158, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Jewett HJ, Strong GH. Infiltrating carcinoma of bladder: relation of depth of penetration of bladder wall to incidence of local extension and metastases. J. Urol.55, 366 (1946).
   PubMed Web of Science ®Google Scholar
• Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer66(3), 543–548 (1990).
   PubMed Web of Science ®Google Scholar
• Smits G, Schaafsma E, Kiemeney L et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology52(6), 1009–1013 (1998).
   PubMed Web of Science ®Google Scholar
• Orsola A, Trias I, Raventos CX et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur. Urol.48(2), 231–238 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng L, Weaver AL, Neumann RM et al. Substaging of T1 bladder carcinoma based on the depth of invasion measured by micrometer: a new proposal. Cancer86, 1035–1043(1999).
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann RM, Weaver AL et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J. Clin. Oncol.17(10), 3182–3187 (1999).
   PubMed Web of Science ®Google Scholar
• Esrig D, Freeman JA, Elmajian DA et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J. Urol.156, 1071–1076 (1996).
   PubMed Web of Science ®Google Scholar
• Nijnou Ngninkeu B, Lorge F, Moulin P et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J. Urol.169(1), 149–152 (2003).
   Google Scholar
• Malkowicz SB. Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Semin. Urol. Oncol.15, 169–178 (1997).
   Google Scholar
• Stein JP, Grossfeld GD, Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J. Urol.160, 645–659 (1998).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol.127, 250–252 (1982).
   PubMed Web of Science ®Google Scholar
• Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol.153, 1823–1826 (1995).
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol.163(1), 73–78 (2000).
   PubMed Web of Science ®Google Scholar
• Flamm J, Havelec L. Factors affecting survival in primary superficial bladder cancer. Eur. Urol.17, 113–118 (1990).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol.150, 60–64 (1993).
   PubMed Web of Science ®Google Scholar
• Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J. Urol.130(6), 1083–1086 (1983).
   PubMed Web of Science ®Google Scholar
• Jakse G, Loidl W, Seeber G et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol.137, 39–43 (1987).
   PubMed Web of Science ®Google Scholar
• Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol.116, 575–580 (1976).
   PubMed Web of Science ®Google Scholar
• Holmang S, Hedelin H, Anderstrom C et al. Recurrence and progression in low grade papillary urothelial tumors. J. Urol.162(3 Pt 1), 702–707 (1999).
   PubMed Web of Science ®Google Scholar
• Lebret T, Bohin D, Kassardjian Z et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette–Guerin instillations. J. Urol.163(1), 63–67 (2000).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology66(6 Suppl. 1), 90–107 (2005).
   PubMed Web of Science ®Google Scholar
• Witjes JA, Kiemeney LA, Schaafsma HE et al. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br. J. Urol.73, 172–176 (1994).
   PubMedGoogle Scholar
• Van der Meijden A, Sylvester R, Collette L et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J. Urol.164(5), 1533–1537 (2000).
   PubMed Web of Science ®Google Scholar
• Freeman JA, Esrig D, Stein JP et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer76(5), 833–839 (1995).
   PubMed Web of Science ®Google Scholar
• Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol.162, 74–76 (1999).
   PubMed Web of Science ®Google Scholar
• Schips L, Augustin H, Zigeuner RE et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology59, 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer progression and recurrence. J. Urol.130, 1083–1086 (1983).
   PubMed Web of Science ®Google Scholar
• Pauwels RP, Schapers RF, Smeets AW et al. Grading in superficial bladder cancer (1) morphological criteria. Br. J. Urol.61, 129–134 (1988).
   PubMedGoogle Scholar
• Abel PD, Hall RR, Williams G. Should pT1 transitional cell cancers of the bladder be classified as superficial? Br. J. Urol.62, 235–239 (1988).
   PubMedGoogle Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–475 (2006).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA, Witjes JA, Heijbroek RP et al. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur. J. Cancer11, 1621–1625 (1994).
   Google Scholar
• Riddle P, Chism G, Trott P et al. Flat carcinoma in situ of bladder. Br. J. Urol.47, 829–833 (1976).
   Google Scholar
• Lamm DL. Carcinoma in situ. Urol. Clin. North Am.19, 499–508 (1992).
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose bacillus Calmette–Guérin for carcinoma in situ of the bladder: long-term results. J. Urol.163, 68–72 (2000).
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder long-term results of EORTC GU Group Phase II protocol 30861. Eur. Urol.40, 144–150 (2001).
   PubMed Web of Science ®Google Scholar
• Parmar MK, Freedman LS, Hargreave TB et al. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on superficial bladder cancer (Urological Cancer Working Party). J. Urol.142(2 Pt 1), 284–288 (1989).
   PubMed Web of Science ®Google Scholar
• Ali-El-Dein B, Sarhan O, Hinev A et al. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. Br. J. Urol. Int.92(4), 393–399.
   Google Scholar
• Herr HW. Bladder cancer: natural history and implications for urothelial cancer prevention. J. Cell. Biol. Chem.16I, 112–119 (1992).
   Google Scholar
• Bostwick DG. Natural history of early bladder cancer. J. Cell. Biochem.16I, 31–38 (1992).
   Google Scholar
• Fitzpatrick JM, West AB, Butler MR et al. Superficial bladder tumors (stage pTa, grades 1 and 2), the importance of recurrence pattern following initial resection. J. Urol.,135, 920–922 (1986).
   PubMedGoogle Scholar
• Cheng L, Cheville JC, Neumann RM et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer85(11), 2469–2474 (1999).
   PubMed Web of Science ®Google Scholar
• Reuter VE. Pathology of bladder cancer: assessment of prognostic variables and response to therapy. Semin. Oncol.17, 524–532 (1990).
   PubMedGoogle Scholar
• Lapham RL, Grignon D, Ro JY. Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens. Semin. Diagn. Pathol.14, 109–122 (1997).
   Google Scholar
• Buscarini M, Quek ML, Gill P et al. Molecular prognostic factors in bladder cancer. Br. J. Urol. Int.95(6), 739–742 (2005).
   Google Scholar
• Dyrskjot L, Zieger K, Kruhoffer M et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res.11(11), 4029–4036 (2005).
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, Goebell PJ, Ebert T et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. Urol.38(6), 691–699 (2000).
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Tonilol G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol.164(3 Pt 1), 680–684 (2000).
   PubMed Web of Science ®Google Scholar